HK1205127A1 - Solid forms of an antiviral compound - Google Patents

Solid forms of an antiviral compound

Info

Publication number
HK1205127A1
HK1205127A1 HK15105959.1A HK15105959A HK1205127A1 HK 1205127 A1 HK1205127 A1 HK 1205127A1 HK 15105959 A HK15105959 A HK 15105959A HK 1205127 A1 HK1205127 A1 HK 1205127A1
Authority
HK
Hong Kong
Prior art keywords
solid forms
antiviral compound
antiviral
compound
solid
Prior art date
Application number
HK15105959.1A
Other languages
English (en)
Chinese (zh)
Inventor
Robert William Scott
Fang Wang
Bing Shi
Erik Mogalian
Original Assignee
Gilead Pharmasset Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gilead Pharmasset Llc filed Critical Gilead Pharmasset Llc
Publication of HK1205127A1 publication Critical patent/HK1205127A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/38Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
HK15105959.1A 2012-06-05 2015-06-23 Solid forms of an antiviral compound HK1205127A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261655934P 2012-06-05 2012-06-05
US201361759295P 2013-01-31 2013-01-31
US13/800,374 US8969588B2 (en) 2012-06-05 2013-03-13 Solid forms of an antiviral compound
PCT/US2013/044138 WO2013184698A1 (fr) 2012-06-05 2013-06-04 Formes solides d'un composé antiviral

Publications (1)

Publication Number Publication Date
HK1205127A1 true HK1205127A1 (en) 2015-12-11

Family

ID=49670993

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15105959.1A HK1205127A1 (en) 2012-06-05 2015-06-23 Solid forms of an antiviral compound

Country Status (20)

Country Link
US (4) US8969588B2 (fr)
EP (1) EP2855478B1 (fr)
JP (2) JP2015518891A (fr)
KR (1) KR20150028971A (fr)
CN (2) CN105524050A (fr)
AR (1) AR091259A1 (fr)
AU (1) AU2013271768B2 (fr)
BR (1) BR112014030400A2 (fr)
CA (1) CA2875507A1 (fr)
ES (1) ES2694759T3 (fr)
HK (1) HK1205127A1 (fr)
IL (1) IL236004A0 (fr)
IN (1) IN2014MN02644A (fr)
MX (1) MX2014014563A (fr)
PT (1) PT2855478T (fr)
RU (1) RU2014150437A (fr)
SG (1) SG11201408013WA (fr)
TW (1) TW201408661A (fr)
UY (1) UY34844A (fr)
WO (1) WO2013184698A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2726998T3 (es) 2003-05-30 2019-10-11 Gilead Pharmasset Llc Análogos de nucleósidos fluorados modificados
RS55249B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
TWI510480B (zh) 2011-05-10 2015-12-01 Gilead Sciences Inc 充當離子通道調節劑之稠合雜環化合物
SG10201602044WA (en) 2011-09-16 2016-04-28 Gilead Pharmassett Llc Methods For Treating HCV
US9056860B2 (en) 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
TW201446286A (zh) * 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
CA2852867C (fr) 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combinaison de formulation de deux composes antiviraux
CN104211565A (zh) * 2013-05-31 2014-12-17 浙江九洲药业股份有限公司 一种抗丙型肝炎药物中间体的制备方法
MX2016002185A (es) 2013-08-27 2016-06-06 Gilead Pharmasset Llc Formulacion combinada de dos compuestos antivirales.
CN104513223B (zh) * 2014-11-20 2017-07-14 上海众强药业有限公司 芴乙酮衍生物的制备方法
JP2018505201A (ja) 2015-02-13 2018-02-22 サンド・アクチエンゲゼルシヤフト レジパスビルおよびソホスブビルを含む医薬組成物
WO2016145269A1 (fr) 2015-03-12 2016-09-15 Teva Pharmaceuticals International Gmbh Formes solides de lédipasvir et procédés pour la préparation de lédipasvir
CN104788361B (zh) * 2015-04-21 2017-06-30 杭州科巢生物科技有限公司 5‑氮杂螺[2.4]庚烷‑6‑甲酸衍生物的合成方法
WO2016193919A1 (fr) 2015-06-05 2016-12-08 Mylan Laboratories Limited Forme polymorphe de ledipasvir
CN104961733B (zh) * 2015-07-06 2019-04-09 上海众强药业有限公司 雷迪帕韦晶型及其制备方法
CN106608870A (zh) * 2015-10-26 2017-05-03 广东东阳光药业有限公司 一种制备雷迪帕韦杂质的方法
WO2017072596A1 (fr) * 2015-10-26 2017-05-04 Optimus Drugs (P) Ltd Procédé amélioré pour la préparation de lédipasvir
CN105237517B (zh) * 2015-10-30 2017-10-27 南京正大天晴制药有限公司 结晶的雷迪帕韦化合物及其制备方法
WO2017072714A1 (fr) 2015-10-30 2017-05-04 Lupin Limited Prémélange de ledipasvir stable et son procédé de préparation
CN105237384B (zh) * 2015-11-06 2017-06-30 上海万溯化学有限公司 一种多取代芴衍生物的制备方法
WO2017197036A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères spirocycliques pour la dégradation de protéines cibles
WO2017197055A1 (fr) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Dégronimères hétérocycliques pour la dégradation de protéines cibles
EP3455218A4 (fr) 2016-05-10 2019-12-18 C4 Therapeutics, Inc. Dégronimères de type glutarimide liés au carbone c3 pour la dégradation de protéines cibles
CN106008316B (zh) * 2016-06-17 2018-04-27 成都百事兴科技实业有限公司 一种合成雷迪帕韦手性中间体的方法
CN111202744A (zh) * 2016-12-26 2020-05-29 上海博志研新药物技术有限公司 一种雷迪帕韦和索非布韦复方片剂及其制备方法和应用
US10392370B2 (en) 2017-03-13 2019-08-27 Optimus Drugs Pvt Ltd Process for the preparation of Daclatasvir dihydrochloride and its intermediates
CN109053400A (zh) * 2018-08-24 2018-12-21 江苏工程职业技术学院 一种雷迪帕韦关键中间体的制备方法
US11378965B2 (en) 2018-11-15 2022-07-05 Toyota Research Institute, Inc. Systems and methods for controlling a vehicle based on determined complexity of contextual environment
CN109678686A (zh) * 2018-12-19 2019-04-26 江苏工程职业技术学院 一种抗丙肝药物雷迪帕韦关键中间体的制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5001139A (en) 1987-06-12 1991-03-19 American Cyanamid Company Enchancers for the transdermal flux of nivadipine
US4992445A (en) 1987-06-12 1991-02-12 American Cyanamid Co. Transdermal delivery of pharmaceuticals
US6482847B2 (en) * 2000-10-03 2002-11-19 Hoffmann-La Roche Inc. Amorphous form of cell cycle inhibitor having improved solubility and bioavailability
CA2537132A1 (fr) * 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Chlorhydrate de valganciclovir amorphe
CN100448879C (zh) * 2004-07-22 2009-01-07 北京化工大学 一种无定型头孢呋辛酯的制备方法
US20100076047A1 (en) * 2007-08-20 2010-03-25 Sankar Reddy Budidet Amorphous 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol phosphate salt
KR20100031045A (ko) * 2008-09-11 2010-03-19 씨제이제일제당 (주) 아데포비어 디피복실의 정제방법
RS55249B8 (sr) 2009-05-13 2021-06-30 Gilead Pharmasset Llc Antiviralna jedinjenja
US20120135965A1 (en) * 2009-05-20 2012-05-31 Ranbaxy Laboratories Limited Amorphous fosamprenavir calcium
KR20120052231A (ko) * 2009-10-16 2012-05-23 이데미쓰 고산 가부시키가이샤 함플루오렌 방향족 화합물, 유기 일렉트로루미네선스 소자용 재료 및 그것을 사용한 유기 일렉트로루미네선스 소자
WO2011156757A1 (fr) 2010-06-10 2011-12-15 Gilead Sciences, Inc. Combinaison de composés anti-vhc avec de la ribavirine pour le traitement du vhc
EP2797586A1 (fr) * 2011-12-29 2014-11-05 AbbVie Inc. Compositions solides
US9056860B2 (en) 2012-06-05 2015-06-16 Gilead Pharmasset Llc Synthesis of antiviral compound
CA2852867C (fr) * 2013-01-31 2016-12-06 Gilead Pharmasset Llc Combinaison de formulation de deux composes antiviraux

Also Published As

Publication number Publication date
BR112014030400A2 (pt) 2016-06-07
US9139570B2 (en) 2015-09-22
JP2017128605A (ja) 2017-07-27
CA2875507A1 (fr) 2013-12-12
US8969588B2 (en) 2015-03-03
CN104379584A (zh) 2015-02-25
AR091259A1 (es) 2015-01-21
AU2013271768B2 (en) 2018-05-17
ES2694759T3 (es) 2018-12-27
TW201408661A (zh) 2014-03-01
EP2855478B1 (fr) 2018-08-08
CN105524050A (zh) 2016-04-27
US20130324496A1 (en) 2013-12-05
EP2855478A1 (fr) 2015-04-08
JP2015518891A (ja) 2015-07-06
US9682987B2 (en) 2017-06-20
KR20150028971A (ko) 2015-03-17
US20150141659A1 (en) 2015-05-21
US20170327488A1 (en) 2017-11-16
PT2855478T (pt) 2018-11-21
RU2014150437A (ru) 2016-08-10
MX2014014563A (es) 2015-07-06
US20150344488A1 (en) 2015-12-03
AU2013271768A1 (en) 2015-01-15
IN2014MN02644A (fr) 2015-10-16
SG11201408013WA (en) 2015-01-29
WO2013184698A1 (fr) 2013-12-12
IL236004A0 (en) 2015-02-01
UY34844A (es) 2013-12-31

Similar Documents

Publication Publication Date Title
HK1205127A1 (en) Solid forms of an antiviral compound
IL258327A (en) Synthesis of antiviral compounds
HK1245263A1 (zh) 抗病毒化合物
IL252345A0 (en) Antiviral compounds
SG10201703451RA (en) Antiviral compounds
HK1211924A1 (en) Solid forms of an antiviral compound
EP2842955A4 (fr) COMPOSÉ INHIBITEUR DE Trk
HK1208677A1 (en) Antiviral compounds with an imidazole - biphenyl - imidazole core --
GB201220843D0 (en) Compound
HK1199454A1 (en) Antiviral compounds
HK1211919A1 (en) Synthesis of an antiviral compound
HK1204618A1 (en) Antiviral compounds
EP2892529A4 (fr) Utilisations de (-)-perhexiline
ZA201502350B (en) Solid form of hihydro-pyrido-oxazine derivative
GB201216309D0 (en) Compound
GB201215675D0 (en) Compound
EP2699241A4 (fr) Composés antiviraux
ITMI20122036A1 (it) Sintesi di un intermedio di un composto antivirale
GB201216448D0 (en) Compound
ZA201402374B (en) Antiviral compounds
ITMI20121668A1 (it) Sintesi di un intermedio di un composto antivirale
LT2928896T (lt) Dihidro-pirido-oksazino darinio kieta forma
TWM433525U (en) Structure of calorifier
GB201222716D0 (en) Compound